These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17441729)

  • 1. NMR solution structure of neurotensin in membrane-mimetic environments: molecular basis for neurotensin receptor recognition.
    Coutant J; Curmi PA; Toma F; Monti JP
    Biochemistry; 2007 May; 46(19):5656-63. PubMed ID: 17441729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermolecular interactions between the neurotensin and the third extracellular loop of human neurotensin 1 receptor.
    Da Costa G; Bondon A; Coutant J; Curmi P; Monti JP
    J Biomol Struct Dyn; 2013 Dec; 31(12):1381-92. PubMed ID: 23140271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation by NMR solution of neurotensin in small unilamellar vesicle environment: molecular surveys for neurotensin receptor recognition.
    Da Costa G; Bondon A; Delalande O; Mouret L; Monti JP
    J Biomol Struct Dyn; 2013; 31(8):809-17. PubMed ID: 22928939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY.
    Seebach D; Lukaszuk A; Patora-Komisarska K; Podwysocka D; Gardiner J; Ebert MO; Reubi JC; Cescato R; Waser B; Gmeiner P; Hübner H; Rougeot C
    Chem Biodivers; 2011 May; 8(5):711-39. PubMed ID: 21560227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of lactam-bridged neurotensin analogues adjusting psi(Pro10) close to the experimentally derived bioactive conformation of NT(8-13).
    Bittermann H; Einsiedel J; Hübner H; Gmeiner P
    J Med Chem; 2004 Oct; 47(22):5587-90. PubMed ID: 15481995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist induced conformation alteration of neurotensin receptor and the mechanism behind Na+ inhibition of 125I-NT binding.
    Mitra SP; Carraway RE; Blute R; Luber-Narod J
    J Recept Signal Transduct Res; 1999 Nov; 19(6):995-1021. PubMed ID: 10533985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NMR-derived conformation of neuropeptide AF, an orphan G-protein coupled receptor peptide.
    Miskolzie M; Kotovych G
    Biopolymers; 2003 Jun; 69(2):201-15. PubMed ID: 12767123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide backbone modifications on the C-terminal hexapeptide of neurotensin.
    Einsiedel J; Hübner H; Hervet M; Härterich S; Koschatzky S; Gmeiner P
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2013-8. PubMed ID: 18276136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR solution structure of the mitochondrial F1beta presequence from Nicotiana plumbaginifolia.
    Moberg P; Nilsson S; Ståhl A; Eriksson AC; Glaser E; Mäler L
    J Mol Biol; 2004 Mar; 336(5):1129-40. PubMed ID: 15037074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation--a review.
    Kleczkowska P; Lipkowski AW
    Eur J Pharmacol; 2013 Sep; 716(1-3):54-60. PubMed ID: 23500196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues.
    Sefler AM; He JX; Sawyer TK; Holub KE; Omecinsky DO; Reily MD; Thanabal V; Akunne HC; Cody WL
    J Med Chem; 1995 Jan; 38(2):249-57. PubMed ID: 7830267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neurotensin--structure, origin and biological function].
    Kulińska-Niedziela I; Paluszak J
    Postepy Hig Med Dosw; 1997; 51(3):329-42. PubMed ID: 9333784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the environment of neurotensin whilst bound to the neurotensin receptor by solid state NMR.
    Williamson PT; Bains S; Chung C; Cooke R; Watts A
    FEBS Lett; 2002 May; 518(1-3):111-5. PubMed ID: 11997028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotensin, schizophrenia, and antipsychotic drug action.
    Kinkead B; Nemeroff CB
    Int Rev Neurobiol; 2004; 59():327-49. PubMed ID: 15006494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The solution structure of the periplasmic domain of the TonB system ExbD protein reveals an unexpected structural homology with siderophore-binding proteins.
    Garcia-Herrero A; Peacock RS; Howard SP; Vogel HJ
    Mol Microbiol; 2007 Nov; 66(4):872-89. PubMed ID: 17927700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotensin protects pancreatic beta cells from apoptosis.
    Coppola T; Béraud-Dufour S; Antoine A; Vincent JP; Mazella J
    Int J Biochem Cell Biol; 2008; 40(10):2296-302. PubMed ID: 18456542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo behavioral effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier.
    Kokko KP; Hadden MK; Price KL; Orwig KS; See RE; Dix TA
    Neuropharmacology; 2005 Mar; 48(3):417-25. PubMed ID: 15721174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of novel multimeric neurotensin(8-13) analogs.
    Hultsch C; Pawelke B; Bergmann R; Wuest F
    Bioorg Med Chem; 2006 Sep; 14(17):5913-20. PubMed ID: 16735124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular cloning and functional characterization of a type-I neurotensin receptor (NTR) and a novel NTR from the bullfrog brain.
    Li JH; Sicard F; Salam MA; Baek M; LePrince J; Vaudry H; Kim K; Kwon HB; Seong JY
    J Mol Endocrinol; 2005 Jun; 34(3):793-807. PubMed ID: 15956348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescein-labeled stable neurotensin derivatives.
    Maes V; Hultsch C; Kohl S; Bergmann R; Hanke T; Tourwé D
    J Pept Sci; 2006 Aug; 12(8):505-8. PubMed ID: 16671056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.